Intervention

DTG/3TC

ClinicalTrials.gov intervention label

Clinical trials6

Recruiting1

Common conditions6

Lead sponsors shown4

Clinical trials

6 shown

Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral ExperienceNCT07031063 · 2025-04-01

A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY)NCT07816250 · 2026-10-19

NOT_YET_RECRUITING

B/F/TAF to DTG/3TC Switch StudyNCT06444620 · 2024-07-22

ACTIVE_NOT_RECRUITING

Good-first: B/F/TAF As First-line ARTNCT06619288 · 2024-07-01

A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAFNCT05911360 · 2023-07-07

A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral TherapyNCT05917509 · 2023-07-06

Common conditions

HIV Infections3 HIV Infection2 Antiretroviral Treatment1 HIV1 HIV-1-infection1 Metabolic Syndrome1

Leading sponsors

ViiV Healthcare3 Affiliated Hospital of Nantong University1 Instituto Mexicano del Seguro Social1 University of Nairobi1

Trial status mix

COMPLETED2

ACTIVE_NOT_RECRUITING1

NOT_YET_RECRUITING1

RECRUITING1

UNKNOWN1

Phase mix

PHASE33

PHASE21

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.